Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daromun neoadjuvant treatment versus standard of care in resectable stage IIIB/C melanoma
2021-003064-27Phase 3Active
- Sponsor
- Philogen
- Start
- Nov 2021
- Modality
- Immunomodulatory ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in cutaneous melanoma (CM) and primary cutaneous melanoma (CM) comparing Daromun neoadjuvant arm with Standard of care control arm (2 arms). Primary endpoint: recurrence-free survival. Started Nov 2021; status: active.
02
Drugs
darleukin
03
Conditions
cutaneous melanoma (CM)primary cutaneous melanoma (CM)
Beyond the preview
Go deeper on 2021-003064-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003064-27.